FBR Capital reiterated an Outperform rating on Evolent Health (NYSE: EVH), and raised the price target to $24.00 (from $16.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Mergers and Acquisitions

Leerink Partners Remains Bullish on Evolent Health (EVH) Following Investor Call July 13, 2016 1:31 PM Evolent Health (EVH) to Acquire Valence Health in $145M DealJuly 13, 2016 8:52 AM Evolent Health to Acquire Valence Health, Extending Breadth and Depth of Value-Based Care OfferingJuly 13, 2016 6:00 AM